Core Viewpoint - The company, Rhein Biotech (002166), has confirmed that it has sufficient production capacity for plant extracts and maintains a stock of malic acid to meet market demand promptly [1] Group 1 - The company has adequate production capacity for plant extracts [1] - The company holds a certain inventory of malic acid, allowing it to respond to market needs at any time [1]

Group 1 - The company, Rhein Biotech (002166.SZ), confirmed that its plant extraction capacity is sufficient to meet market demand [2] - The company has a certain inventory of oridonin, allowing it to respond to market needs at any time [2]

Group 1 - The company, 莱茵生物, confirmed that the plant extract, 莽草酸, is one of the raw materials for the production of the antiviral drug, 奥司他韦 [2] - The company has mastered the complete extraction process of 莽草酸 and maintains a certain level of inventory to respond to market demand [2]